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Human T lymphotropic virus type 1 (HTLV-1) is an exogenous
retrovirus that establishes a persistent infection in humans.
It infects 10–20 million people worldwide with endemic regions
in Japan, equitorial Africa, the Caribbean and South America (Proietti
et al., 2005). The virus is transmitted from mother to child, between
sexual partners, by needle sharing and in contaminated bloodee front matter & 2012 Elsevier Inc. All rights reserved.
g/10.1016/j.virol.2012.09.028
ing author.
ess: b.asquith@ic.ac.uk (B. Asquith).products. HTLV-1 is a complex retrovirus. So, in addition to the
standard repertoire of structural proteins and enzymes shared by all
retroviridae (gag, pol, pro and env), the 3’region of the HTLV-1
genome (pX region) also encodes a number of accessory genes: tax,
rex, p12, p21, p13, p30 and HBZ. HBZ, HTLV-1 basic leucine zipper
factor, is the only transcript from the antisense strand of the viral
genome (Gaudray et al., 2002).
Research into HTLV-1 is important for two main reasons.
Firstly, HTLV-1 is the aetiological agent of a number of patholo-
gies for which there is no cure and no effective treatment.
Consequently, HTLV-1 is responsible for a signiﬁcant burden of
morbidity and mortality. Research into HTLV-1 pathogenesis aims
L.B. Cook et al. / Virology 435 (2013) 131–140132to alleviate this burden. Secondly, HTLV-1 infection is an excellent
model of within-host pathogen dynamics and immune control.
HTLV-1 succeeds in establishing a persistent infection, often with
a high proviral load (it is not unusual for 45% of PBMC to be
infected) despite a large and chronically activated cellular
immune response. Furthermore, there is considerable between-
individual variation both in clinical status and set point proviral
load. Work to understand how HTLV-I persists and what underlies
the inter-individual variation in outcome has led to fundamental
advances in human immunology. Recently, both areas of research,
pathogenesis and viral persistence, have started to converge with
several lines of enquiry pointing to the central importance of the
viral-encoded protein HBZ. Here we review recent progress in
HTLV-1 pathogenesis and some of the lessons in immunology
learnt from HTLV-1.HTLV-1 pathogenesis
HTLV-1 and disease
HTLV-1 is causatively associated with a number of patholo-
gies; the two most common are adult T-cell leukaemia (ATL)
and HTLV-associated myelopathy/tropical spastic paraparesis
(HAM/TSP). ATL is a spectrum of CD4þ T cell malignancies that
is categorised into four types: acute, chronic, smouldering and
lymphoma; the acute form is the most common and is rapidly
fatal. HAM/TSP is a chronic progressive myelopathy characterised
by spastic paraparesis. Only a minority of HTLV-1-infected indi-
viduals develop disease. Depending on ethnicity and gender,
approximately 2–3% of infected individuals develop ATL and
0.25–4% develop HAM/TSP (Hisada et al., 2004; Osame et al.,
1990; Tajima, 1990). Other associated diseases include HTLV-
associated uveitis and infective dermatitis. The majority of
infected individuals remain lifelong asymptomatic carriers (ACs).
The mechanisms by which HTLV-1 causes such diverse clinical
diseases are not understood and it is also not known why disease
typically occurs decades after initial infection and affects less than
10% of carriers. Understanding of HTLV-1-associated disease is
further limited by the lack of suitable animal models and inacces-
sibility of tissue from the central nervous system of individuals.
Since no viral genotype has been associated with any particular
disease (Furukawa et al., 2000) and there is a large antiviral immune
response, the currently accepted hypothesis is that the host immune
response is the main determinant of the risk of disease (Kannagi
et al., 2011; Kannagi et al., 2004).
ATL
ATL is typically characterised by monoclonal CD4þ CD25þ
T-lymphocytes carrying a single provirus. Clonal expansion is
thought to be driven by the expression of proviral genes (Tax/
HBZ) counter-balanced by the HTLV-1-speciﬁc immune response.
Clones that become long lived may undergo genetic damage and
subsequent malignant transformation (Etoh et al., 1997). Until
recently the protein Tax was considered to be critical both for
leukemogenesis and viral persistence because of its interactions
with host genes responsible for cell proliferation, DNA repair, cell
cycle control, and apoptosis (Marriott and Semmes, 2005) and
because of its associations with cell proliferation in vitro (Portis,
Harding, and Ratner, 2001) and in vivo (Asquith et al., 2007).
However, Tax expression is only detected in about 30% of freshly
isolated samples from ATL cases. Tax expression can be disrupted
by deletion or CpG hypermethylation of the 5’LTR, which is the
promoter and enhancer for transcription from the forward strand,
leading to silencing of forward strand transcription (Taniguchiet al., 2005) and genetic mutations in Tax itself leading to
silencing ((Takeda et al., 2004), section ‘‘Immunogenicity of
HTLV-I-infected cells’’). These ﬁndings cast doubt on the hypoth-
esis that continued expression of Tax is essential in the late stages
of leukaemogenesis (Satou et al., 2006; Takeda et al., 2004).
In contrast to Tax, HBZ mRNA has been detected in 100% of ATL
cells (Fan et al., 2010; Satou et al., 2006). HBZ possesses prolif-
erative functions and suppression of HBZ transcription by short
interfering RNA decreased ATL cell proliferation (Satou et al.,
2006). Recently HBZ-transgenic mice have been demonstrated to
develop tumours (Satou et al., 2011). Current opinion favours the
role of Tax in the initiation of ATL and HBZ to maintain the
transformed phenotype.
HAM/TSP
Immunostaining of post mortem biopsies shows that early in
the disease process the leptomeninges, blood vessels and par-
enchyma are inﬁltrated with CD4þ , CD8þ , B lymphocytes and
foamy macrophages, whereas later in the disease CD8þ lympho-
cytes predominate with subsequent progression to a relatively
acellular, atrophic pattern with axonal and myelin degeneration
(Iwasaki et al., 1992). HTLV-1-infected cells are present in the
cerebrospinal ﬂuid and are typically present at greater than twice
their frequency in the peripheral blood (Hayashi et al., 2008;
Kubota et al., 1994) reﬂecting either recruitment or expansion of
HTLV-1-infected cells in the central nervous system. However,
there is no evidence that HTLV-1 directly infects neuronal cells,
astrocytes or microglia. HTLV-1 speciﬁc CD8þ lymphocytes that
secrete the neurotoxic cytokines interferon g (IFNg) and tumour
necrosis factor are present (Greten et al., 1998) and may be
responsible for bystander damage (Hoger et al., 1997; Yamano
et al., 2002).
In a recent study Tattermusch et al. compared blood transcrip-
tional proﬁles of asymptomatic carriers, patients with HAM/TSP
and seronegative control subjects. The authors found that at a
given proviral load, the presence of disease was associated with
overexpression of a distinct subset of IFN-stimulated genes. This
signature was absent in healthy HTLV-1 carriers and correlated
positively with the clinical severity of HAM/TSP (Tattermusch
et al., 2012). However it remains unclear whether chronic over-
expression of IFN-stimulated genes contributes to the tissue
damage seen in HAM/TSP or is merely a consequence of the
inﬂammatory condition.
Determinants of proviral load
HTLV-1 proviral load (the number of integrated copies of
HTLV-1 expressed as a proportion of PBMCs) remains approxi-
mately stable in one individual over years, but may vary 1000-
fold between individuals (Demontis et al., 2012; Matsuzaki et al.,
2001). A high proviral load is one of the best predictors of HAM/
TSP and ATL, although many patients with a high load will remain
lifelong asymptomatic carriers (Iwanaga et al., 2010; Nagai and
Osame, 2003). However, there is little longitudinal data to con-
ﬁrm that a high proviral load is the cause of disease rather than
the consequence (Kira et al., 1991; Taylor et al., 1999). Never-
theless, given the association between proviral load and disease a
number of studies have attempted to elucidate the determinants
of proviral load.
Integration and clonal expansion
Following T cell infection, HTLV-1 genomic RNA is reverse
transcribed and integrated into the host cellular genomic DNA.
Cellular proliferation results in large clonal expansions of infected
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(Wattel et al., 1996). Recently Gillet et al. used high throughput
sequencing to investigate clone distribution and abundance as a
function of proviral integration site (Gillet et al., 2011). The
principal ﬁndings were that (i) in vitro integration was biased
towards transcriptionally active regions of the genome but that
these sites were counterselected in vivo, (ii) the increase in proviral
load seen in patients with HAM/TSP (compared with asymptomatic
carriers) is due to the presence of an increased number of clones,
(iii) the largest clones were associated with proximity to CpG
islands, host genes and activating epigenetic marks and this
distribution differed between asymptomatic carriers, HAM/TSP
and ATL, (iv) among established abundant T cell clones, integration
of the provirus in the same transcriptional orientation as the nearby
host gene also drives selective expansion.
CD8þ T cell lysis
A method to quantify the rate at which naturally, endogen-
ously infected cells are cleared by autologous CD8þ cytotoxic
T-lymphocytes (CTL) ex vivo, has been developed (Asquith et al.,
2005). This ex vivo lysis assay was used to quantify the relation-
ship between the strength of the CTL response and HTLV-1
proviral load. Correlation of the rate of CTL lysis with HTLV-1
proviral load showed a signiﬁcant inverse relationship (Asquith
et al., 2005; Kattan et al., 2009). Thus, individuals with a high rate
of clearance of infected cells tended to have a low proviral load.
This correlation was found both in ACs and in HAM/TSP patients.
A negative correlation does not necessarily imply that the rate of
CTL lysis determines proviral load; the opposite could also be
true. However, the efﬁcient, perforin-dependent reduction in
Taxþ cells by CTL ex vivo provides a plausible mechanism by
which CTL killing rate could determine proviral load. This analysis
showed that a large proportion of the variation between indivi-
duals in HTLV-1 proviral load can be explained by the rate at
which CTLs kill infected cells. In both the ACs and the HAM/TSP
patients 40–50% of the inter-individual variation in proviral load
could be accounted for by variation in antiviral efﬁcacy, thereby
being the largest single predictor of inter-individual variation in
HTLV-1 proviral load (Asquith et al., 2005).1 NK receptor genes (with or without their ligand) have no effect of the
outcome of HTLV-I infection. This is not to be confused with NK receptor genes in
the context of particular protective or detrimental HLA class I molecule where a
clear effect on outcome is seen. See Section ‘‘Innate receptors enhance the HLA
class I-restricted response’’.The immune response to HTLV-1
The observation that the HTLV-1 sequence is conserved
(Gessain et al., 1992) and the ﬁnding of large clones of infected
cells (Wattel et al., 1996) suggests that HTLV-1 replicates pre-
dominantly by driving mitosis of infected cells rather than by
de novo infection of previously uninfected target cells. Addition-
ally, HTLV-1 is largely cell-associated and produces few virions
(Derse et al., 2001). Thus, although the HTLV-I-speciﬁc antibody
titre is high, particularly in HAM/TSP (Enose-Akahata et al., 2012;
Manns et al., 1999), antibody surveillance is thought to be largely
ineffective (Dumenil, 2011).
Similarly, there is little evidence that natural killer (NK) cells
play an important role in controlling HTLV-I infection. CD56þCD3
NK cells have no detectable lytic activity against HTLV-1-infected
target cells. This is true whether the targets are naturally infected
CD4þ cells isolated from PBMC of HTLV-1-infected subjects or
when the targets are produced in vitro by infection of primary
CD4þ T cells (Banerjee et al., 2007; Hanon et al., 2000). NK cells
may have little effect on HTLV-1-infected cells because, unlike
many viruses, HTLV-1 does not appear to cause signiﬁcant down-
modulation of inhibitory NK ligands or upregulation of activating
ligands. In particular, surface MHC class I expression is not
signiﬁcantly downregulated in primary HTLV-1-infected cells
(Yoshida et al., 2000) although the HTLV-1 accessory proteinp12I has been shown to cause some down-modulation on T-cell
lines (Johnson et al., 2001). Additionally, ligands for the NK cell
activating receptors, NCR and NKG2D are not expressed by HTLV-
1-infected cells (Banerjee et al., 2007): all these factors are likely
to reduce NK cell recognition of HTLV-1-infected cells. Further-
more, in contrast to human immunodeﬁciency virus (HIV-1) and
hepatitis C virus (HCV) (Khakoo et al., 2004; Martin et al., 2002;
Martin et al., 2007), there is no evidence from immunogenetic
studies that particular NK receptor genes are associated with the
outcome of HTLV-1 infection1 (O’Connor et al., 2012; Seich al
Basatena et al., 2011). Again, these observations argue against a
major role for NK cells in HTLV-I infection.
In contrast there is compelling evidence that the CD8þ
cytotoxic T lymphocyte (CTL) response is an important determi-
nant of the outcome of HTLV-I infection (Bangham, 2009).
Perhaps the most convincing is the strong association between
certain human leucocyte antigen (HLA) class I alleles and the
outcome of infection (see Section ‘‘Determinants of protective
immunity’’ below).Determinants of protective immunity
A number of associations between particular HLA class I alleles
and proviral load and clinical outcome have been identiﬁed. In a
Japanese cohort, possession of HLA-An02 and Cn08 was associated
with a signiﬁcant decrease in the odds of HAM/TSP and a signiﬁcant
decrease in proviral load amongst asymptomatic carriers of the
virus. In contrast, HLA-Bn54 was detrimental. Carriers of Bn54 were
signiﬁcantly more likely to have HAM/TSP and, amongst individuals
with HAM/TSP, Bn54 was associated with a signiﬁcant increase in
proviral load (Jeffery et al., 2000; Jeffery et al., 1999).
In HIV-1 infection, protective HLA class I alleles tend to be those
that bind epitopes in more conserved regions of the genome. More
conserved regions are presumably those that need to be maintained
to preserve viral function. Epitopes in conserved regions are likely to
reduce the chance of viral escape from the CTL response and may
result in a heavier ﬁtness cost when escape does occur (Borghans
et al., 2007; Kiepiela et al., 2007). In contrast to HIV-1, HTLV-I is
highly genetically stable (Kubota et al., 2007) and, whilst viral
variants that can escape CTLs do occur (Niewiesk et al., 1995), there
is little evidence that these variants have a net selective advantage
in asymptomatic carriers or HAM/TSP patients (Gessain et al., 1992)
though a number of studies have highlighted the importance of viral
mutants in ATL (Furukawa et al., 2001; Furukawa et al., 2006; Koiwa
et al., 2002; Takeda et al., 2004). Certainly, the phenomenon of viral
escape from CTL, which is prevalent in HIV-1 infection (Goonetilleke
et al., 2009), is not a deﬁning feature of HTLV-1 infection in the
absence of malignancy. HLA class I-associated protection from HAM/
TSP is therefore unlikely to be correlated with targeting invariant
regions of the viral genome. Studying the mechanisms underlying
HLA class-I associations in HTLV-I infection thus provides additional
information about the determinants of protective immunity.
Using a combination of epitope prediction (MacNamara et al.,
2009) and ex vivo cellular work it has been shown that the
protective HLA class I alleles HLA-An02 and Cn08 bind epitopes
from the viral protein HBZ signiﬁcantly more strongly than the
detrimental molecule HLA-Bn54 (MacNamara et al., 2010). In a
cohort of 432 HTLV-I-infected individuals from Kagoshima in
Japan, carriage of HLA class I molecules which bind HBZ epitopes
Table 1
HLA class I binding of peptides from different HTLV-1 proteins has a differential
impact on both proviral load and HAM/TSP risk. Left hand column: The HTLV-1
proteins were ranked according to whether they targeting them was associated with
asymptomatic status. This list could be viewed as the ‘‘rank order of targets for a
vaccine designed to reduce HAM/TSP risk’’. Right hand column: The HTLV-1 proteins
were ranked according to whether targeting them was associated with reduced
proviral load. This list could be viewed as the ‘‘rank order of targets for a vaccine
designed to reduce proviral load’’. List reproduced from (MacNamara et al., 2010).
Rank order of protein targets associated with reducing
HAM/TSP risk Proviral load
HBZ Gag
Pol HBZ
Gag Pol
p21 Rex
Tax Tof
Rex p21
p13 Pro
Tof Tax
Pro p13
p12 p12
Rof Rof
Env Env
L.B. Cook et al. / Virology 435 (2013) 131–140134strongly was signiﬁcantly associated with asymptomatic status.
This was true for both HLA-A and HLA-B molecules (HLA-C was
not studied). Importantly, these associations held even after
carriers of HLA-An02, Cn08 and Bn54 were excluded from the
cohort, demonstrating that the protective effect of binding HBZ
was common to many HLA alleles and was not just a feature of a
few particular alleles. Additionally, in both asymptomatic carriers
and HAM/TSP patients, carriage of HLA alleles which could bind
epitopes from HBZ strongly was associated with a signiﬁcant
reduction in proviral load (MacNamara et al., 2010).
This work suggests that HLA class I binding of epitopes from HBZ
is associated with good control of HTLV-I and reduced risk of HAM/
TSP. This raises the question why is binding of HBZ epitopes
particularly protective? We hypothesise that an HTLV-1-infected cell
which represses expression of all viral genes except HBZ has a
survival advantage because it can escape from the host immune
response against these proteins but maintains the ability to pro-
liferate at an elevated rate (see Section ‘‘Persistence in the face of a
strong immune response’’). This dual action – reduction of HTLV-1
expression (and subsequent protection from immune surveillance),
and enhancement of infected cell proliferation – probably confers a
survival advantage on HBZ-expressing cells. That HBZ-expressing
cells have a survival advantage is consistent with the observations
that HBZ enhances persistence in HTLV-1 inoculated rabbits
(Li et al., 2009). We suggest that if HBZ-speciﬁc CD8þ T cells are
weak or absent then infected cells that express HBZ but not other
viral proteins will evade immune surveillance and proliferate
rapidly, leading to an increase in proviral load. HBZ-speciﬁc CD8þ
T cells would then play an important role in preventing this
proliferation of provirus-positive cells and blocking this strategy of
persistence. We hypothesise that the requirement for HBZ expres-
sion is one of the few weak points in HTLV-1’s lifecycle and thus
HBZ-speciﬁc CD8þ T cells are unusually protective.Fig. 1. HLA class I binding of peptides from different HTLV-1 proteins has a
correlated impact on both proviral load and HAM/TSP risk. The HTLV-1 proteins
were ranked according to whether they were bound signiﬁcantly more strongly by
asymptomatic carriers or HAM/TSP patients (x-axis; at the extremes ACs were
signiﬁcantly more likely to bind peptides from HBZ, HAM/TSP patients were
signiﬁcantly more likely to bind peptides from Env). This list could be viewed as
the ‘‘rank order of targets for a vaccine designed to reduce HAM/TSP risk’’. Proteins
were also ranked according to whether binding their peptides was associated with
a lower proviral load (y-axis; at the extremes binding of HBZ was associated with
a signiﬁcantly lower proviral load, binding of Env was associated with a
signiﬁcantly higher proviral load). This list could be viewed as the ‘‘rank order
of targets for a vaccine designed to reduce proviral load’’. These two sets of ranks
were positively correlated (Rs¼0.86, P¼0.0005, Spearman’s rank correlation).
That is, proteins whose peptides are bound by asymptomatic carriers (right hand
side of the graph) are, independently, those associated with a lower proviral load
when bound (top of the graph); (MacNamara et al., 2010).Immunodominance
Initially, it was postulated (Jeffery et al., 1999) that HLA-An02
was protective because it bound an epitope (Tax 11–19) from the
dominant CTL target antigen Tax with unusually high avidity and
restricted high frequency HTLV-1-speciﬁc CD8þ T cell responses
(Jacobson et al., 1990). More generally, Tax-speciﬁc CD8þ T were
often considered as the best candidate for ‘efﬁcient’ or ‘protective’
CD8þ cells because Tax is the immunodomminant antigen (Goon
et al., 2004).2 Our ﬁnding that binding of HBZ peptides rather than
Tax peptides is protective challenges the assumption that immu-
nodominant responses are necessarily protective. Interestingly, in
contrast to Tax, HBZ is very poorly immunogenic. We found that
the frequency of HBZ-speciﬁc CD8þ T cells is signiﬁcantly lower
than the frequency of Tax-speciﬁc CD8þ T cells in the same
person and, consistent with this, that the predicted binding
afﬁnity of HLA molecules to HBZ peptides is signiﬁcantly weaker
than that of Tax peptides (Hilburn et al., 2011; MacNamara et al.,
2010). Although we would predict that, given the central impor-
tance of HBZ in maintaining HTLV-1 persistence, HTLV-1 would
have evolved to minimise HBZ immunogenicity, it is nevertheless
striking that these low frequency T cell responses are so important.
More generally, it was possible to rank all the HTLV-1 proteins
by whether binding their peptides was associated with a reduced
risk of HAM/TSP (Table 1). This list could be viewed as the ‘‘rank
order of targets for a vaccine designed to reduce HAM/TSP risk’’.2 The immunodominant antigen can be deﬁned in different ways: the antigen
that is most often recognised, the antigen eliciting the largest response (e.g. by
IFNg ELISpot), or the antigen eliciting the largest response after correction for
different protein lengths. Tax is immunodominant by all three measures.Additionally, it was possible to rank all the HTLV-1 proteins by
whether binding their peptides was associated with a reduced
proviral load. This list could be viewed as the ‘‘rank order of
targets for a vaccine designed to reduce proviral load’’. These two
lists are produced independently (as the proviral load list is
calculated separately in ACs and HAM/TSP patients) and one does
not follow trivially from the other. The two lists are strongly
positively correlated (Rs¼0.86, P¼0.0005, Spearman’s rank cor-
relation) providing a validation of this approach (Fig. 1). This work
has a number of implications:1. HLA class I binding of peptides from different proteins has a
differential impact on both proviral load and HAM/TSP risk. So far
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Seic
or c
asso
rem
cell
and
et a
L.B. Cook et al. / Virology 435 (2013) 131–140 135we have investigated why targeting one extreme example (HBZ)
may be beneﬁcial. Much is still to be understood, such as why
targeting say Gag is better than targeting Pol or why targeting p12
is apparently so ineffective (or perhaps actively detrimental?)2. We have established a ranked list of protein targets of the most
efﬁcient CD8þ T cell response through to the least efﬁcient
response. Identiﬁcation of protective epitopes immediately sug-
gests a practical approach to measure and enhance, via vaccina-
tion, the efﬁciency of an individual’s anti-viral response.3. Finally, the observation that was made for HBZ–speciﬁc
responses (that immunogenicity is not correlated with protec-
tion) is extended and supported by this work. Even if we
exclude HBZ, there is no correlation between the magnitude of
a response (after correction for protein length) and protection
from HAM/TSP (Rs¼0.20, p¼0.64) or between magnitude
and reduction in viral load (Rs¼0.57, p¼0.14) (Goon et al.,
2004; Hilburn et al., 2011; MacNamara et al., 2010). Conclu-
sions are unchanged if we do not correct for protein length
(Rs¼0.33, p¼0.42. Rs¼0.14, p¼0.74) or if we deﬁne the
immunodominance hierarchy by the frequency of recognition
(Rs¼0.22, p¼0.61. Rs¼0.24, p¼0.57).
‘‘Innate’’ receptors enhance the HLA class I-restricted response
Immunogenetics studies of HTLV-1 infection have revealed
another determinant of protective immunity: killer immunoglobulin-
like receptor (KIR) genotype. The KIRs are a family of receptors that
are expressed on NK cells and subsets of T cells, particularly effector
memory CD8þ T cells (Anfossi et al., 2001). The KIR family contains
both inhibitory and activating receptors. The majority of the inhibi-
tory KIR (KIR2DL1, KIR2DL2/3, KIR3DL1 and KIR3DL2) as well as an
activating KIR (KIR2DS1) bind allotypes of HLA class I molecules. The
ligands of most of the activating KIR are still unknown. An individual’s
KIR functionality is determined by three factors: the number of KIR
genes that individual possesses (individuals typically carry between
7 and 14 KIR genes with varying numbers of inhibitory and activating
KIR), which alleles of these polymorphic genes are present, and which
HLA ligands (if any) of the KIRs are present (Khakoo and Carrington,
2006).. 2. Proposed mechanism to explain inhibitory KIR enhancement of HLA class I associa
h al Basatena’s observations do not appear to be compatible with direct NK-killing for f
linical status in either HTLV-1 or HCV; secondly most of the HLA molecules which
ciations were enhanced and ﬁnally the protective effect of binding HBZ was enhanced,
iniscent of T cells (Seich al Basatena et al., 2011). Instead we hypothesise that the dow
responses by increasing the survival of memory CD8þ T cells. Either because (i) inhib
protection from exhaustion (Gati et al., 2003; Ugolini et al., 2001; Young et al., 2001) (
l., 2007; Soderquest et al., 2011). Image reproduced from (Elemans et al., 2012) baseIt has been shown that a particular inhibitory KIR, namely
KIR2DL2, is associated with an enhancement of HLA class I-
mediated immunity in HTLV-I infection (Seich al Basatena et al.,
2011). Brieﬂy, it was found that HLA class I associations were
stronger in the presence of KIR2DL2 than in the absence. KIR2DL2-
associated enhancement was seen for both protective and detri-
mental HLA alleles, for multiple HLA-A, B and C molecules and for
two independent metrics (proviral load and protection from
HAM/TSP). Strikingly, exactly the same behaviour (KIR2DL2
enhancement of HLA class I associations) was observed in infec-
tion with an unrelated virus, namely hepatitis C virus (HCV). The
odds of making this observation by chance were less than 1011.
Several associations between KIR and HLA pairs have been
reported in the literature (Khakoo et al., 2004; Martin et al., 2002;
Martin et al., 2007); in every case the KIR:HLA pair was a KIR with
its known or putative ligand and the underlying mechanism was
attributed to NK cells (Fig. 2a). In contrast, the observed KIR2DL2-
associated enhancement of HLA is not readily explained by NK
cells. There are four reasons for this:1.tion
our
wer
NK
nstr
itor
ii) o
d onWhen KIR2DL2 is present with the genes encoding its ligands, but
in the absence of a particular protective or detrimental HLA class I
molecule (i.e. the parallel of the previous studies) there is no effect
on clinical outcome or viral burden in HTLV-1 or HCV infection.2. The majority of the HLA class I molecules whose effects are
enhanced do not appear to bind KIR2DL2 (with the possible
exception of Cn08).3. KIR2DL2 enhances both protective and detrimental HLA class I
associations, a property that is difﬁcult to reconcile with an
NK-mediated effect.4. The protective effect of binding HBZ peptides was enhanced.
Although NK cells display some peptide speciﬁcity, such
marked protein speciﬁcity is more reminiscent of T cells.
We thus hypothesise that the effector cells that are enhanced
by the presence of KIR2DL2 are CD8þ T cells.
This study has two important implications for cellular immunol-
ogy, not only in HTLV-1 infection but more generally. Firstly, it
provides a plausible explanation for the incomplete penetrance of
protective and detrimental HLA class I traits. Although certain HLAs. KIR-HLA associations are typically attributed to direct NK action, (a). However,
reasons: ﬁrstly KIR2DL2 (alone or with its C1 ligands) has no impact on viral load
e enhanced do not bind KIR2DL2, thirdly both protective and detrimental HLA
cells display some peptide speciﬁcity but such marked protein speciﬁcity is more
eam effectors are CD8þ T cells, (b). We postulate that KIR2DL2 enhances CD8þ T
y KIRs on CD8þ T cells are associated with reduced activation induced cell death
r inhibitory KIRs on NK cells reduce NK-killing of activated CD8þ T cells (Cerboni
an image in (Seich al Basatena et al., 2011).
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ibility there are numerous examples of individuals who are not
consistent with the general trend. For example, in HIV-1 infection,
although elite controllers are heavily enriched for HLA-Bn57, the
phenomenon of B57þ individuals who progress to AIDS at normal
rates is well described (Chen et al., 2012). Similarly, in HTLV-1
infection, although HLA-Cn08 is protective (associated with reduced
risk of HAM/TSP and reduced proviral load in asymptomatic
carriers) it is not associated with a reduced proviral load amongst
HAM/TSP patients (Jeffery et al., 1999). And HLA-Bn54, which is
detrimental (associated with increased risk of HAM/TSP and
increased proviral load in HAM/TSP patients), is not associated with
increased proviral load in asymptomatic carriers (Jeffery et al.,
2000). If an additional gene (KIR2DL2) needs to be present for an
HLA class I molecule to be effective then this could explain why the
protective or detrimental effects of particular HLA alleles are not
always manifest. Secondly, the suggestion that KIR2DL2 is associated
with an enhancement of CD8þ T cell responses points to a novel
role for KIR in adaptive immunity. We have hypothesised that
KIR2DL2 enhances adaptive immunity by increasing the survival
of memory CD8þ T cells. Interestingly, studies in ankylosing
spondylitis have also implicated inhibitory KIR in the survival and
aberrant expansion of autoreactive T cells (Bowness et al., 2011).
There are at least two mechanisms by which inhibitory KIRs could
increase CD8þ T cell survival (Fig. 2b): via their expression on CD8þ
T cells (Fig. 2b (i)) or NK cells (Fig. 2b (ii)). It is known that KIRs are
expressed on CD8þ ab T cells (Fig. 2b (i)) with an effector memory
phenotype (CD28-CD45RA-CD45ROþCCR7-) (Anfossi et al., 2001)
and have been reported in chronic infections including HTLV-1,
HCV, EBV, CMV and HIV-1 (Alter et al., 2008; Bieganowska et al.,
1999; Bonorino et al., 2007; Poon et al., 2005; van der Veken et al.,
2009). In mice, inhibitory NK receptors (Ly49 receptors, the functional
homologue of human KIRs) increase CD8þ T cell survival (Roger
et al., 2001). Similarly, in KIR-transgenic mice, ligation of inhibitory
KIRs increases the activation threshold of CD8þ T cells and reduces
activation induced cell death (Anfossi et al., 2001; Ugolini et al., 2001;
Ugolini and Vivier, 2000). Consistent with this, inhibitory KIRs on
human T cells are associated with higher levels of the survival
molecule Bcl-2 and lower levels of cell death (Young et al., 2001).
Alternatively (Fig. 2b (ii)), it is known that NK cells help down-
modulate the acute response by killing activated T cells and that this
killing is reduced by inhibitory receptors expressed on NK cells
(Cerboni et al., 2007; Soderquest et al., 2011). In both these scenarios,
CD8þ T cells would survive longer in the presence of inhibitory KIRs
and thus the protective and detrimental HLA class I associations
would be enhanced. Interestingly, this may explain an early ﬁnding
that the in vivo survival of memory T cells required MHC class I
molecules but not the restricting allele (Tanchot et al., 1997). At the
time this result was difﬁcult to understand as it was assumed that the
survival signal came from the T cell receptor (TCR); but it can be
explained by the requirement for MHC to bind the inhibitory NK
receptor rather than the TCR. The NK cell-dependent pathway
(depicted in Fig. 2b (ii)) could also proceed via a ‘‘third-party’’ cell
e.g. dendritic cells (DCs) or CD4þ T cells. Cross-talk between NK cells
and DCs inﬂuences adaptive immunity (Raulet, 2004). However, this
interaction is not thought to be inﬂuenced by KIR (Della Chiesa et al.,
2003; Vitale et al., 2005). Interestingly, control of antiviral CD8þ T
cell frequency via NK cell-mediated modulation of CD4þ T cell help
has recently been described in LCMV-infected mice (Waggoner et al.,
2011).Persistence in the face of a strong immune response
HTLV-1-speciﬁc CTL in the peripheral blood of asymptomatic
carriers and HAM/TSP patients are frequent, chronically activatedand have immediate effector function ex vivo (Hanon et al., 2000;
Jacobson et al., 1990). Yet as far as we know HTLV-1 is rarely, if
ever, cleared (there are few documented case of HTLV-1 seropo-
sitivity in the absence of infected cells). Furthermore, HTLV-1
often persists at a high level: in a Japanese cohort the mean HTLV-
I proviral copy number was 798 per 104 PBMC in HAM/TSP
patients; and 120 per 104 PBMC in asymptomatic carriers
(Nagai et al., 1998). How HTLV-1 persists so successfully in the
face of an apparently strong CTL response is a subject of great
interest. The answer appears to be two-fold. Firstly, HTLV-I
appears to have evolved to minimise the immunogenicity of
infected cells. Secondly, even when this mechanism is subverted
and immunogenicity is increased, CTL killing appears to be less
effective than was previously thought.
Immunogenicity of HTLV-I-infected cells
The immunogenicity of HTLV-1-infected cells is reduced by the
inhibition of the transcription of viral genes from the positive
strand (i.e. all genes with the exception of HBZ). This inhibition is
achieved via multiple mechanisms:(i) HBZ interacts with cellular factors to suppress Tax-mediated
transactivation through the 5’ LTR and thereby inhibits
expression of HTLV-1 genes on the positive strand (Basbous
et al., 2003a; Gaudray et al., 2002).(ii) The HTLV-1 provirus acquires mutations which prevent
expression of viral proteins. In both ATL and asymptomatic
carriers, APOBEC3G-generated nonsense mutations, deletions
and insertions which result in loss or truncation of the viral
protein are frequent in all viral proteins except HBZ (Fan
et al., 2010). Abortive genetic changes may be less frequent in
HBZ either because they are generated less frequently in HBZ
and/or because they are selected against. It has been sug-
gested that APOBEC3G generates less nonsense mutations in
HBZ because HBZ has less APOBEC3G target sequences than
any other HTLV-1 gene (Fan et al., 2010).(iii) Additionally, ATL cells often have a hypermethylated or
deleted 5’ LTR but an intact functional 3’ LTR (Satou et al.,
2006). This will prevent transcription of genes on the forward
strand but not HBZ which is transcribed from the 3’ LTR.Thus, via multiple mechanisms, the expression of all viral
proteins except HBZ is repressed. Additionally, there is evidence
that HBZ may directly reduce the immunogenicity of infected
cells. It has been shown in HBZ-transgenic CD4þ T cells that an
anti-inﬂammatory phenotype is induced with inhibition of IFN-g
production (Sugata et al., 2012), enhanced sensitivity to TGF-b,
and enhanced expression of the regulatory transcription factor
FoxP3 (Zhao et al., 2011). This may also facilitate immune evasion.
Simultaneously, HBZ induces cellular proliferation. The exact
molecular mechanism by which HBZ induces cellular proliferation
is unknown. But it is known that HBZ can modulate cellular
transcription and signalling pathways, interacting with p300 via
its N-terminal activating domain (Clerc et al., 2008), and c-Jun,
JunB, CREB and CREB-2 via its leucine zipper domain (Basbous
et al., 2003b; Gaudray et al., 2002; Hivin et al., 2007; Thebault
et al., 2004). Interestingly, HBZ RNA alone is sufﬁcient to promote
the proliferation of infected T-lymphocytes (Satou et al., 2006).
HTLV-1 replicates within the host mainly by mitosis of infected
cells rather than production of virions. Therefore, HTLV-1 does
not need to express all the viral genes to replicate. By suppressing
expression of the genes on the positive strand the immunogeni-
city of infected cells is reduced. By retaining HBZ expression,
HTLV-I-infected cells are driven to proliferate and proviral load is
increased.
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a rabbit model. Molecular clones of HTLV-1 which were deleted
for HBZ could efﬁciently infect rabbit T cells in vitro and in vivo,
however viral loads of HBZ-deleted viruses were consistently
signiﬁcantly lower than wild type HTLV-1, both in early and late
infection (Arnold et al., 2006). Thus, while not essential for
infection, HBZ contributes to viral persistence.
So the data are consistent with a picture in which expression
of all viral genes except HBZ is repressed thereby helping to evade
immune surveillance. Expression of HBZ needs to be retained in
order to drive infected cell replication. In this picture HBZ
expression would be the one weak point which exposed infected
cells to the CTL response and would therefore be a crucial target
for an effective CTL response. This would explain the ﬁnding that
HTLV-I-infected individuals with HLA class I molecules which
bind HBZ peptides with high afﬁnity have reduced proviral load
and reduced HAM/TSP risk (see section ‘‘Determinants of
protective immunity’’ and (MacNamara et al., 2010)).
Slow clearance of Tax-expressing cells in vivo
Given the number of mechanisms to reduce the expression of
virus proteins one might predict that if these mechanisms were
overcome then virus-infected cells would be rapidly killed by CTL.
This appears not to be the case. In vitro and in BLV-infected sheep
in vivo, sodium valproate, a histone deacetylase inhibitor, acti-
vates the expression of Tax and p19 core protein (other viral
proteins were not studied) (Achachi et al., 2005; Lezin et al., 2007;
Lezin et al., 2009). When given orally to HAM/TSP patients,
sodium valproate caused a transient reduction in proviral load
in all 19 subjects studied (Lezin et al., 2007; Olindo et al., 2011)
consistent with the activation of viral expression in infected cells
and subsequent destruction by the host immune system. How-
ever, the rate of clearance of infected cells was unexpectedly slow.
By ﬁtting a mathematical model to the data from valproate-
treated HAM/TSP patients the in vivo rate of CTL lysis of viral-
protein expressing cells has been estimated at 0.03–0.13 d1
(Elemans et al., 2012). This means that, if infected cells were
not replaced, then it would take between 5 and 23 days for half of
the infected cells to be killed. This is considerably slower than
ex vivo estimates of the rate of CTL lysis, which are approximately
1 d1. This translates into a half life of approximately 1 day for an
HTLV-1-infected CD4þ T cell ex vivo (Asquith et al., 2005).
Discrepancies between in vitro and in vivo estimates are not
uncommon and are probably attributable to factors such as the
time CTL need to ﬁnd their target which will be very different
in vivo and in vitro. Interestingly, the rate of CTL killing of HTLV-1-
infected cells in vivo is of the same order of magnitude as in vivo
estimates for HIV-1 (Asquith et al., 2006) and SIV (Asquith and
McLean, 2007; Elemans et al., 2011a; Elemans et al., 2011b;
Mandl et al., 2007) obtained using independent methods.Concluding remarks
We conclude by outlining some of the major questions arising
from the work reviewed here.
Is HBZ a viable target for HTLV-I vaccine design?
The central importance of HBZ in viral persistence makes HBZ
a rational target for vaccine design. However, HBZ contains few
peptides that are predicted to bind HLA class I molecules well
(MacNamara et al., 2010): a feature that may help explain its poor
immunogenicity. A lack of potential CTL epitopes is concerning.
Nevertheless, the fact that between-individual differences inHBZ binding have such a large impact on clinical outcome is
exciting. Possession of one or more alleles that can bind HBZ
peptides was associated with the prevention of 48% of cases of
HAM/TSP in a study cohort (MacNamara et al., 2010). This
suggests that vaccines to boost HBZ-speciﬁc immunity could
result in a large reduction HAM/TSP risk, at least in individuals
with HLA class I molecules that permit HBZ binding.
Why is CTL killing low in vivo?
To date, the only intervention that has resulted in a convincing
reduction in HTLV-1 proviral load is treatment with sodium
valproate. Sodium valproate has an excellent safety proﬁle and
treatment caused a reproducible reduction in proviral load (Lezin
et al., 2007; Olindo et al., 2011). However, the CTL killing of
infected cells in vivo was slow and proviral load was not
suppressed in the long term (Elemans et al., 2012; Olindo et al.,
2011). Mouse studies and ex vivo work with HTLV-1-speciﬁc CTL
indicate that CTL killing has the potential to be remarkably
effective both in vivo and ex vivo (Asquith et al., 2005; Barber
et al., 2003; Regoes et al., 2007). Understanding why CTL killing is
low in vivo in HTLV-1 infection, even after viral gene expression
has been activated, may be key to achieving a more rapid and
sustained reduction in proviral load following treatment with
sodium valproate.
How do KIRs affect the outcome of HTLV-1 infection?
KIR genotype has a striking impact on the outcome of HTLV-1
infection: KIR2DL2 is associated with a 6-fold increase in the odds
of remaining asymptomatic in the context of the protective HLA
molecule Cn08 and a 12-fold increase in the risk of developing
HAM/TSP in the context of the detrimental molecule Bn54 (Seich
al Basatena et al., 2011). Understanding how KIR2DL2 interacts
with the adaptive response to determine clinical outcome may
suggest new pathways to reduce HAM/TSP risk. The observation
that KIR2DL2 is also associated with the enhancement of HLA
class I associations in HCV infections suggests that KIR2DL2
enhancement of the HLA class I-restricted response may be a
general mechanism and thus of interest and importance for the
wider immunology research community.
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